Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer
- Sponsor
- Hunan Province Tumor Hospital
- Study ID
- NCT05055999
- Status
- Completed
Conditions
- Extensive Stage Small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- First line EC/EP+Atezolizumab — DRUGEtoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day
Study Details
The purpose of the trial is to detect tumor microenvironment on Extensive Stage Small Cell Lung Cancer with simultaneous liver metastases who Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy.
Key Dates
- Start date
- Apr 1, 2019
- Status verified
- Apr 2019
- Primary completion
- Jul 1, 2021
- Completion
- Sep 1, 2021
Study Design
- Enrollment
- 60 participants (actual)
Primary Outcome Measure
PFS [ Time Frame: April 2019- July 2021 ]
Related Studies
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerPHASE2 · Recruiting · Muhammad Furqan · Chicago, Illinois
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerPHASE2 · Recruiting · Hirva Mamdani · Indianapolis, Indiana
- Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)PHASE1 · Recruiting · Amgen · Los Angeles, California
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)PHASE1 · Recruiting · Amgen · Gilbert, Arizona